Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-19
2006-12-19
Wison, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S359000, C546S112000, C546S113000, C546S119000, C546S121000, C548S100000, C548S125000, C548S126000
Reexamination Certificate
active
07151104
ABSTRACT:
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyridine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
REFERENCES:
patent: 6107305 (2000-08-01), Misra et al.
patent: 6730789 (2004-05-01), Birault et al.
patent: WO 97/16452 (1997-05-01), None
patent: WO 01/35917 (2001-05-01), None
patent: WO 02/50079 (2002-06-01), None
Vesely et al., “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”,Eur. J. Biochem(1994), 224: 771-786.
Senderowicz et al., “Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients With Refractory Neoplasms”,Journal of Clinical Oncology(Sep. 1998), 16(9): 2986-2999.
Meijer et al., “Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5”,Eur. J. Biochem.(1997), 243: 527-536.
Bible et al., “Cytotoxic Synergy between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration”,Cancer Research(Aug. 15, 1997), 57: 3375-3380.
Shiota et al., “Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-α]pyrimidine”,Chem. Pharm. Bull.(1999), 47(7): 928-938.
Yasuo Makisumi et al., “Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-α]pyrimidines.”,Chem Pharm. Bull.(1962), 10: 620-626.
Aboul-Fadl et al., “Effective and Variable Functionalization of Pyrazolo[1,5-α]pyridines Involving Palladium-Catalyzed Coupling Reactions”,Synthesis 2000, (12): 1727-1732.
Nathanael Gray et al., “ATP-site Directed Inhibitors of Cyclin-dependent Kinases”,Current Medicinal Chemistry, 6(9): 859-875, (1999).
Adrian M. Senderowicz et al., “Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators”,Journal of the National Cancer Institute, 92(5): 376-387 (Mar. 1, 2000).
Doll Ronald J.
Dwyer Michael P.
Girijavallabhan Viyyoor M.
Guzi Timothy J.
Keertikar Kartik M.
Kalyanaraman Palaiyur S.
Schering Corporation
Ward Paul V.
Wison James O.
LandOfFree
Pyrazolopyridines as cyclin dependent kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyridines as cyclin dependent kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyridines as cyclin dependent kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3681927